Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.63 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15148025 | 0.88 | NR1H2 (0.72) | NR1H2NR1H3GPR119PTPN1 | |
| SCHEMBL17749010 | 0.88 | NR1H2 (0.49) | NR1H2NR1H3ALDH1A1LMNAMAPT | |
| SCHEMBL21886120 | 0.88 | NR1H2 (0.72) | NR1H2NR1H3GPR119PTPN1 | |
| SCHEMBL12324594 | 0.88 | NR1H2 (0.72) | NR1H2NR1H3GPR119PTPN1 | |
| SCHEMBL17754100 | 0.87 | NR1H2 (0.48) | NR1H2NR1H3ALDH1A1LMNAMAPT | |
| SCHEMBL25606205 | 0.86 | NR1H2 (0.63) | NR1H2NR1H3ALDH1A1LMNAMAPT | |
| SCHEMBL16570088 | 0.85 | MAPT (0.63) | NR1H2NR1H3ALDH1A1LMNAMAPT | |
| SCHEMBL29828720 | 0.84 | NR1H2 (0.53) | NR1H2NR1H3 | |
| SCHEMBL29097213 | 0.84 | NR1H2 (0.53) | NR1H2NR1H3 | |
| SCHEMBL30172596 | 0.83 | NR1H2 (0.66) | NR1H2NR1H3ALDH1A1MAPTNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108613-B | Bromodomain inhibitors and uses thereof | 基因泰克公司 | 2020-02-25 | — | — | CN | disclosed |
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3218376-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | NR1H2 319/4885NR1H3 268/4885ALDH1A1 1563/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | NR1H2 319/4885NR1H3 268/4885ALDH1A1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.